NextCure Stock Explodes 200 Percent After Announcing 320 Million Dollar Merger With Psoriasis Drug Developer Avere Therapeutics

NextCure's stock surged over 200 percent in a single session after the struggling biotech announced an all-stock merger with privately held Avere Therapeutics and a concurrent $320 million financing round that positions the combined company to advance a once-weekly oral treatment for psoriasis into late-stage trials.

The triple-digit gain ranks among the largest biotech merger-and-acquisition premiums of 2026, reflecting investor enthusiasm for Avere's lead asset, AVR-001, an IL-23 receptor antagonist designed to treat moderate-to-severe plaque psoriasis—a chronic inflammatory skin condition affecting more than 8 million Americans.

Under the merger agreement announced in July, Avere shareholders will own approximately 75 percent of the combined company, with NextCure shareholders retaining 25 percent. The deal values NextCure's existing operations at roughly $85 million, a steep discount from its $400 million market capitalization at IPO in 2019. But for a company that laid off half its workforce in 2024 after multiple clinical setbacks, the merger offers something more valuable than valuation: survival.

What Makes AVR-001 Different

AVR-001 is a cyclic peptide engineered to block the IL-23 receptor, a key driver of inflammation in psoriasis and other autoimmune diseases. What sets it apart from existing treatments is its pharmacokinetic profile: the drug has a half-life of approximately 100 hours, enabling once-weekly oral dosing. Most current IL-23 inhibitors require injections every few weeks or months.

Oral, weekly dosing could reshape the psoriasis market, which generated over $12 billion in global sales in 2025. Patients consistently prefer pills over injections when efficacy is comparable, and compliance rates for oral therapies tend to run 20 to 30 percentage points higher than injectable alternatives. If AVR-001 clears Phase 3 trials, it could capture a meaningful slice of a market currently dominated by AbbVie's Skyrizi and Johnson & Johnson's Tremfya.

Avere has already completed a Phase 1 trial demonstrating AVR-001's safety and tolerability. The $320 million financing—led by Fairmount Funds and China's Hansoh Pharmaceutical—will fund two Phase 2 studies in psoriasis and a potential expansion into ulcerative colitis, another IL-23-driven inflammatory disease.

The China Connection

Hansoh's involvement extends beyond its role as a lead investor. Avere separately entered an exclusive licensing agreement with Hansoh covering Greater China, granting the Chinese pharmaceutical giant rights to develop and commercialize AVR-001 in mainland China, Hong Kong, Macau, and Taiwan. Hansoh paid $120 million upfront and committed to up to $2.18 billion in development and sales milestones, plus mid-single-digit to low-double-digit royalties on net sales.

The Hansoh deal validates AVR-001's commercial potential and provides Avere with non-dilutive capital to fund global development. It also reflects a broader shift in biotech deal-making: Chinese pharmaceutical companies are increasingly willing to pay premium prices for promising assets in inflammatory and autoimmune diseases, markets where Western innovation still holds an edge but Chinese patient populations are massive.

NextCure's Fall and Avere's Rise

NextCure became a public company in 2019 on the strength of its immuno-oncology pipeline, raising $133 million in an IPO that valued the company at $400 million. But its lead programs stumbled in mid-stage trials, and by late 2024, NextCure had burned through most of its cash. The company laid off more than 50 employees and slashed its R&D budget by 70 percent, funding operations through 2026 with no clear path forward.

The Avere merger is effectively a reverse takeover disguised as a merger of equals. Avere executives will lead the combined company, which will rebrand and trade under the ticker AVRX once the transaction closes in the second half of 2026. NextCure's public-market infrastructure—its Nasdaq listing, existing shareholder base, and regulatory compliance framework—becomes the vehicle for Avere to go public without the cost and complexity of a traditional IPO.

For NextCure shareholders, the deal is a bitter pill. Their stake gets diluted to 25 percent, and the company they invested in is gone in all but name. But the alternative—liquidation or a fire-sale acquisition—would have been worse. At least this way, they're along for the ride if AVR-001 succeeds.

What Happens Next

The merger is expected to close before the end of 2026, pending regulatory approvals and shareholder votes. Once complete, Avere will have roughly two years of cash to advance AVR-001 through Phase 2 trials in psoriasis and ulcerative colitis. Positive data from those studies could position the company for a pivotal Phase 3 program in 2028 or 2029.

If AVR-001 delivers on its promise, Avere could become one of the rare biotech success stories that goes from formation to market in under a decade. If it fails, NextCure's investors will be left with nothing but a 200 percent stock pop on merger day and a reminder that biotech is a long game with short lifespans.